VistaGen Therapeutics, Inc. has rebounded from clinical development setbacks before, but investors imposed a severe penalty on the South San Francisco biotech on 22 July following its pre-market announcement that social anxiety disorder candidate PH94B failed to meet the primary endpoint in the first of two pivotal Phase III trials.
Trading at only $1.07 per share at the beginning of the day on 22 July – despite a clinical pipeline...